Apr 18, 2021
[2 min Read]
CloudMD is a telehealth firm that strives to provide an expanding list of services to the North American market. This is done through aggresive acqusiitons, through which CloudMD has also been expanding to new reigons all over the continent. CloudMD's stock has seen a 52-week growth of 171.62%, which can be contributed to the series of consistent catalysts. These catalysts consist of acquistions and new product offerings, which has led to an exponential increase in marketshare and consumers.
The two most influential catalysts that have led to the explosivness of CloudMD's stock price are:
CloudMD On Demand
The launch of CloudMD On Demand quickly led to a worldwide spotlight being shun on the telehealth provider, as the service provides individuals to meet with a doctor through a conference call within minutes. The doctor can also provide prescriptions through the app, which are directly sent to a pharmacy of the consumers choice. Since the introduction of CloudMD On Demand, all major additions in service lines have been intergrated within the platform to provide users with an all-in-one solution.
The acqusition that started the exponential explosivness of CloudMD's share price was its takeover of Snapclarity, an online platform that provides accessible mental healthcare solutions through its Saas platform. The $6.8 million acqusition made CloudMD one of the only telemedicine companies that provides an integrated digital platform which combines top-tier primary care with clinically-proven mental health support. Snapclarity services has been seamlessly integreated into the CloudMD On Demand platform, providing consumers with an all-in-one access to critical services in an highly accessible manner.
Rather than penetrating new markets through natural growth, CloudMD has instead chosen to pursue aggressive takovers to add to its ever growing On Demand platform. This has resulted in a diverse range of revenue streams, while also providing more doctors to CloudMD On Demand. With Laurentian Bank recently upgrading the target price of CloudMD to $4.20, the future sure looks bright for the telehealth company. Furthermore, people are starting to embrace the conveince of meeting with physicans through an online platform. What once seemed like a pandemic fad has turned into profitable venture with lots of room to grow. While the momentum has certainly cooled off, I expect CloudMD's recent acquisition of Oncidium, one of Canada's largest healthcare management firms, to provide a boost to its shareprice. Furthermore, projections of reporting its first ever profit during their upcoming earnings reports in June also indicates a rising share price. Thus, I expect CloudMD to reach $4 by the end of fiscal year 2021.